RVV

Revive Therapeutics (RVV)

Revive Therapeutics Ltd

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:TSXV:RVV

1 2 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2022/03/29	22:57	InvestorsHub NewsWire	Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19	TSXV:RVV	Revive Therapeutics Ltd
2022/02/24	22:35	InvestorsHub NewsWire	HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical Research	TSXV:RVV	Revive Therapeutics Ltd
2022/02/16	22:03	InvestorsHub NewsWire	Revive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation	TSXV:RVV	Revive Therapeutics Ltd
2022/01/19	22:19	InvestorsHub NewsWire	Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19	TSXV:RVV	Revive Therapeutics Ltd
2022/01/07	22:05	InvestorsHub NewsWire	Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19	TSXV:RVV	Revive Therapeutics Ltd
2021/11/16	22:00	InvestorsHub NewsWire	Revive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta Variant	TSXV:RVV	Revive Therapeutics Ltd
2021/09/22	20:30	InvestorsHub NewsWire	Revive Therapeutics Included in AdvisorShares® Newly Launched Psychedelics ETF	TSXV:RVV	Revive Therapeutics Ltd
2021/09/22	00:50	AllPennyStocks.com	ETF Inclusion Sends Psychedelic Stock Soaring	TSXV:RVV	Revive Therapeutics Ltd
2021/07/16	03:47	InvestorsHub NewsWire	Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trialfor Bucillamine in COVID-19	TSXV:RVV	Revive Therapeutics Ltd
2021/06/17	21:59	InvestorsHub NewsWire	Revive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of Psychedelics	TSXV:RVV	Revive Therapeutics Ltd
2021/06/08	22:12	InvestorsHub NewsWire	Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India	TSXV:RVV	Revive Therapeutics Ltd
2021/05/17	22:48	InvestorsHub NewsWire	Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film Strip	TSXV:RVV	Revive Therapeutics Ltd
2021/04/27	22:51	InvestorsHub NewsWire	Revive Therapeutics Files For FDA Orphan Drug Designation for Psilocybin in Traumatic Brain Injury	TSXV:RVV	Revive Therapeutics Ltd
2021/04/22	21:26	InvestorsHub NewsWire	Revive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional ....cont	TSXV:RVV	Revive Therapeutics Ltd
2021/03/19	20:56	InvestorsHub NewsWire	Revive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of ...Cont	TSXV:RVV	Revive Therapeutics Ltd
2021/02/17	23:53	InvestorsHub NewsWire	Revive Therapeutics Acquires Unique Psilocybin Assets	TSXV:RVV	Revive Therapeutics Ltd
2021/01/18	23:51	InvestorsHub NewsWire	How Combat Sports Are Researching Micro-Dosing Psychedelics To Treat Brain Injuries	TSXV:RVV	Revive Therapeutics Ltd
2021/01/14	22:30	InvestorsHub NewsWire	Revive Therapeutics Announces Research Collaboration with North Carolina State University	TSXV:RVV	Revive Therapeutics Ltd
2020/12/31	22:30	InvestorsHub NewsWire	Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study	TSXV:RVV	Revive Therapeutics Ltd
2020/12/23	23:57	InvestorsHub NewsWire	Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine	TSXV:RVV	Revive Therapeutics Ltd
2020/11/12	23:00	InvestorsHub NewsWire	Revive Therapeutics Provides Update on Oral Thin Film Product with Psilocybin	TSXV:RVV	Revive Therapeutics Ltd
2020/10/20	23:58	InvestorsHub NewsWire	Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds	TSXV:RVV	Revive Therapeutics Ltd
2020/09/29	22:39	InvestorsHub NewsWire	Revive Therapeutics Announces Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19	TSXV:RVV	Revive Therapeutics Ltd
2020/09/21	23:15	InvestorsHub NewsWire	Revive Therapeutics Provides Corporate Update on its Psychedelics Therapeutics Programs	TSXV:RVV	Revive Therapeutics Ltd
2020/09/16	22:59	InvestorsHub NewsWire	Revive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COV...	TSXV:RVV	Revive Therapeutics Ltd
2020/09/02	22:24	InvestorsHub NewsWire	Revive Therapeutics Enters into Clinical Trial Agreement to Evaluate Psilocybin for the Treatment of Methamphetamine Use	TSXV:RVV	Revive Therapeutics Ltd
2014/12/06	02:01	PR Newswire (Canada)	Revive Therapeutics Prices and Files Final Prospectus for Equity Financing	TSXV:RVV	Revive Therapeutics Ltd
2014/06/27	20:00	Marketwired Canada	Revive Therapeutics Ltd. Announces Positive Results of REV-001 Phase 2A Proof-Of-Concept Study	TSXV:RVV	Revive Therapeutics Ltd
2014/06/27	20:00	Marketwired	Revive Therapeutics Ltd. Announces Positive Results of REV-001 Phase 2A Proof-Of-Concept Study	TSXV:RVV	Revive Therapeutics Ltd
2014/06/05	20:00	Marketwired	Revive Therapeutics Ltd. Submits Pre-IND Package to the US FDA for Its Gout Drug Candidate, REV-002	TSXV:RVV	Revive Therapeutics Ltd